{"product_id":"bysi-vrio-analysis","title":"BeyondSpring Inc. (BYSI): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs BeyondSpring Inc. (BYSI) built for lasting success? This concise VRIO analysis cuts straight to the chase, evaluating the Value, Rarity, Inimitability, and Organization of its key assets to determine its true competitive advantage. Dive in now to see the definitive verdict on what truly sets BeyondSpring Inc. (BYSI) apart in the market.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyondSpring Inc. (BYSI) - VRIO Analysis: 1. Plinabulin: First-in-Class Immuno-Oncology Agent\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at BeyondSpring Inc.’s Plinabulin, and the core question is whether its unique mechanism can translate into a sustained market position, especially given the capital situation. Honestly, the clinical data is compelling, but the clock is ticking on the balance sheet.\u003c\/p\u003e\n\n\u003cp\u003ePlinabulin offers a potential standard-of-care shift by resensitizing tumors to checkpoint inhibitors, which is a massive unmet need since over 60% of patients progress on PD-1\/L1 therapies. The Phase 2 investigator-initiated NSCLC cohort (n=47) showed a Disease Control Rate (DCR) of \u003cstrong\u003e85%\u003c\/strong\u003e and a median Progression-Free Survival (PFS) of \u003cstrong\u003e7.0 months\u003c\/strong\u003e after prior PD-1\/L1 failure, which is a strong signal. Also, Phase 1 translational study data showed a DCR of \u003cstrong\u003e54%\u003c\/strong\u003e when combined with radiation and ICIs in ICI-relapsed\/refractory cancers.\u003c\/p\u003e\n\n\u003cp\u003eHere’s a quick look at the key performance indicators from that promising NSCLC data:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eConfirmed Objective Response Rate (ORR): \u003cstrong\u003e18.2%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eMedian Duration of Response (DOR): \u003cstrong\u003e7.2 months\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e12-month Overall Survival (OS): \u003cstrong\u003e79%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe mechanism - maturing dendritic cells (DC) via a specific GEF-H1 dependent pathway - is what sets it apart from other agents in this space. That specific biology is hard to copy quickly. Still, the advantage is only temporary unless the company converts this clinical promise into a commercial reality or a major deal. As of September 30, 2025, cash and cash equivalents stood at \u003cstrong\u003e$12.5 million\u003c\/strong\u003e, and the continuing operations net loss for Q3 2025 was \u003cstrong\u003e$1.7 million\u003c\/strong\u003e. That cash position demands swift action.\u003c\/p\u003e\n\n\u003cp\u003eThe organization is actively working on business development, which is good, but the structure around its SEED Therapeutics stake shows complexity. BeyondSpring currently reports owning about \u003cstrong\u003e38%\u003c\/strong\u003e of SEED, but future sales transactions are expected to reduce this to roughly \u003cstrong\u003e14%\u003c\/strong\u003e. This strategic maneuvering is meant to fund Plinabulin’s late-stage trials, but it also means the value derived from that asset is being monetized now.\u003c\/p\u003e\n\n\u003cp\u003eHere is the VRIO assessment summary for Plinabulin’s core asset profile:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eJustification\/Data Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eDCR \u003cstrong\u003e85%\u003c\/strong\u003e in post-ICI NSCLC cohort (n=47).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eUnique DC maturation mechanism.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eSpecific molecule and established clinical profile are hard to replicate.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eActively pursuing partnerships; Cash \u003cstrong\u003e$12.5M\u003c\/strong\u003e as of 9\/30\/2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eSustained advantage hinges on partnership\/approval before cash runs low.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the execution risk in securing a partnership that fully values the data, especially with the SEED ownership dilution planned. You need to see concrete steps on the partnership front soon. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyondSpring Inc. (BYSI) - VRIO Analysis: 2. Published Global Phase 3 Data (DUBLIN-3 Trial)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Provides the necessary evidence base for regulatory submissions (e.g., NMPA) and commercial discussions, showing durable survival benefits over docetaxel alone.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePlinabulin + Docetaxel (DP)\u003c\/td\u003e\n\u003ctd\u003eDocetaxel Alone (D)\u003c\/td\u003e\n\u003ctd\u003eStatistical Significance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Enrollment (ITT)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003en=278\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003en=281\u003c\/strong\u003e (Total N=\u003cstrong\u003e559\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Endpoint: Mean OS (p-value)\u003c\/td\u003e\n\u003ctd\u003eImproved\u003c\/td\u003e\n\u003ctd\u003eComparator\u003c\/td\u003e\n\u003ctd\u003e$p = \\mathbf{0.03}$ \/ Log-rank $p \u0026lt; \\mathbf{0.04}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Secondary Endpoint: ORR ($P$ value)\u003c\/td\u003e\n\u003ctd\u003eImproved\u003c\/td\u003e\n\u003ctd\u003eComparator\u003c\/td\u003e\n\u003ctd\u003e$P \u0026lt; \\mathbf{0.03}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Secondary Endpoint: PFS ($P$ value)\u003c\/td\u003e\n\u003ctd\u003eImproved\u003c\/td\u003e\n\u003ctd\u003eComparator\u003c\/td\u003e\n\u003ctd\u003e$P \u0026lt; \\mathbf{0.01}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate; many companies have Phase 3 data, but this is for a novel mechanism in a difficult-to-treat population.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSix recent Phase 3 studies in the same population failed to show Overall Survival (OS) benefit versus docetaxel (SAPPHIRE, LEAP-008, CONTACT01, EVOKE-01, CARMEN-LC03, and CANOPY-2).\u003c\/li\u003e\n\u003cli\u003eThe combination demonstrated a clinically meaningful relative improvement in Q-TWiST of \u003cstrong\u003e18.4%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Low; the trial execution and published results in The Lancet Respiratory Medicine are historical facts.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePublication Date: Full data published in \u003cem\u003eThe Lancet Respiratory Medicine\u003c\/em\u003e on September 9, 2024.\u003c\/li\u003e\n\u003cli\u003eTrial Centers: Enrolled patients from \u003cstrong\u003e58\u003c\/strong\u003e medical centers across Australia, China, and the USA.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: High; the data is leveraged immediately in presentations (SITC 2025) and business development efforts.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial\/Operational Data Point\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{\\$1.0}$ million\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{\\$0.6}$ million\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expense Increase Driver\u003c\/td\u003e\n\u003ctd\u003eHigher volume of Plinabulin combination therapy research to support strategic business development\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 vs Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained; published, positive Phase 3 data is a permanent barrier to entry for competitors targeting the same indication with the same drug.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurvival Rate Comparison (DP vs D)\u003c\/td\u003e\n\u003ctd\u003eDP Rate\u003c\/td\u003e\n\u003ctd\u003eD Rate\u003c\/td\u003e\n\u003ctd\u003eP-Value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e24-Month OS Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$P \u0026lt; \\mathbf{0.01}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e36-Month OS Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$P = \\mathbf{0.04}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e48-Month OS Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNot calculated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrade 4 Neutropenia (All Cycles Day 8)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e33.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{85\\%}$ relative reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyondSpring Inc. (BYSI) - VRIO Analysis: 3. SEED Therapeutics Equity Stake (Approx. 38% as of Q3 2025)\n\u003c\/h2\u003e\n\u003cp\u003eThe SEED Therapeutics equity stake represents a significant, though actively managed and diminishing, asset for BeyondSpring Inc.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Proceeds from Sale\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$35.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJanuary 2025 Definitive Agreements \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOwnership Stake (Reported Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e40.12%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2025 (after February 2025 first closing) \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetained Ownership Stake (Expected Final)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUpon completion of future sale transactions \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEED Pre-money Valuation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$100 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeries A-3 financing led by Eisai \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents (BYSI)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.483 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025 \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe strategic rationale for the sale was to generate proceeds to advance BeyondSpring's lead asset, Plinabulin, without diluting shareholder equity. The transactions are part of a broader plan to sell up to \u003cstrong\u003e100%\u003c\/strong\u003e of its interests in SEED, with subsequent closings expected to further decrease the stake.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides indirect exposure to the high-growth, pioneering field of Targeted Protein Degradation (TPD) via a significant, though diminishing, ownership stake. SEED secured U.S. FDA and China NMPA clearance of its Investigational New Drug (IND) application for its lead RBM39 degrader program.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; owning a substantial stake, which was \u003cstrong\u003e40.12%\u003c\/strong\u003e as of Q3 2025, in a recognized TPD leader like SEED, which co-founded with Eli Lilly and Company in 2020, is not common for a company of this size.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; competitors could invest in other TPD firms, but replicating this specific founding stake and the initial ownership structure is impossible. SEED also secured a \u003cstrong\u003e$30 million\u003c\/strong\u003e Series A-3 financing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; the company is actively managing this asset, executing sales agreements to fund Plinabulin development. BeyondSpring retained \u003cstrong\u003econtrol of the SEED Board\u003c\/strong\u003e after the first closing in February 2025.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this advantage erodes as the planned share sales reduce ownership to about \u003cstrong\u003e14.4%\u003c\/strong\u003e by the expected completion of future transactions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eBeyondSpring reported a Q3 2025 net loss of \u003cstrong\u003e$4.944 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyondSpring Inc. (BYSI) - VRIO Analysis: 4. Plinabulin's Unique Dendritic Cell (DC) Maturation Mechanism\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The mechanism, involving DC bridging of innate and adaptive immunity via a specific GEF-H1 pathway, underpins its potential as a broad immune modulator.\u003c\/p\u003e\n\u003cp\u003eClinical data supporting this mechanism includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 1 data across eight cancer types showed a DCR 54% associated with a GEF-H1 dependent DC maturation\/M1 macrophage mechanism.\u003c\/li\u003e\n\u003cli\u003eIn a Phase 2 investigator-initiated NSCLC cohort ($\\text{n}=47$) of patients who progressed after PD-1\/L1 therapy, the regimen demonstrated:\n\u003cul\u003e\n\u003cli\u003eDisease Control Rate (DCR 85%).\u003c\/li\u003e\n\u003cli\u003eMedian Progression-Free Survival (PFS 7.0 months).\u003c\/li\u003e\n\u003cli\u003eObjective Response Rate (ORR 18.2%).\u003c\/li\u003e\n\u003cli\u003eDuration of Response (DOR 7.2 months).\u003c\/li\u003e\n\u003cli\u003e12-month OS 79% and 24-month OS 66%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003ePlinabulin alone or in combination has been well-tolerated in \u0026gt;700 cancer patients in two positive Phase 3 studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; this specific biological pathway activation is a distinct scientific asset in immuno-oncology.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; replicating the precise molecular understanding and clinical validation of this mechanism is a significant R\u0026amp;D hurdle.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; R\u0026amp;D expenses for Plinabulin research increased in Q3 2025 to support partnership initiatives based on this mechanism.\u003c\/p\u003e\n\u003cp\u003eFinancial metrics related to research and development support:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Amount\u003c\/td\u003e\n\u003ctd\u003eQ3 2024 Amount\u003c\/td\u003e\n\u003ctd\u003eChange\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Quarterly)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e$0.4 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Year-to-Date Sept 30)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e$0.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe quarterly R\u0026amp;D expense increase of \u003cstrong\u003e$0.4 million\u003c\/strong\u003e was primarily due to higher drug manufacturing expenses, higher professional service expenses in regulatory affairs, and higher volume of Plinabulin combination therapy research to support strategic business development and partnership initiatives. The quarterly R\u0026amp;D expense represented a 67% year-over-year increase.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; deep scientific understanding and validation of a novel mechanism are hard to copy.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyondSpring Inc. (BYSI) - VRIO Analysis: 5. Clinical Experience Base (Over 700 Patients Treated)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Demonstrates a favorable safety profile across multiple studies and indications, which is crucial for regulatory confidence and physician adoption.\u003c\/p\u003e\n\u003cp\u003eThe safety data is supported by the administration of Plinabulin to over 700 patients with good tolerability, with some reports indicating approximately 800 patients across various clinical studies.\u003c\/p\u003e\n\u003cp\u003eThe DUBLIN-3 Phase 3 trial, which involved 559 patients across 58 medical centers in Australia, China, and the USA, showed that the plinabulin\/docetaxel combination resulted in an over 80% relative reduction in Grade 4 neutropenia compared to docetaxel alone.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; a large patient exposure number for a late-stage asset is valuable, but not unique in the industry.\u003c\/p\u003e\n\u003cp\u003eThe cumulative patient exposure across all trials provides a substantial dataset for safety evaluation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a historical operational achievement that cannot be replicated without running the same trials.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this safety data is a core component of all ongoing regulatory and partnership discussions.\u003c\/p\u003e\n\u003cp\u003eThe safety profile informs ongoing discussions, such as the Phase 2 303 Study in metastatic NSCLC, which enrolled 47 patients.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; the real-world safety data accumulated is a permanent, verifiable asset.\u003c\/p\u003e\n\n\u003cp\u003eKey Statistical Data from Clinical Experience:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudy\/Metric\u003c\/td\u003e\n\u003ctd\u003ePatient Count\u003c\/td\u003e\n\u003ctd\u003eKey Safety\/Demographic Data Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative Patient Exposure\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e700\u003c\/strong\u003e to approximately \u003cstrong\u003e800\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eGood tolerability reported.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDUBLIN-3 Phase 3 Trial (CIN\/NSCLC)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e559\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e80%\u003c\/strong\u003e relative reduction in Grade 4 neutropenia.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 303 Study (NSCLC after ICI)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e47\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e51.1%\u003c\/strong\u003e experienced grade 3 or higher treatment-related adverse effects.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eSpecific Data Points from Phase 2 303 Study (N=47):\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e78%\u003c\/strong\u003e of patients progressed on PD-1\/L1 inhibitors, including those who received pembrolizumab.\u003c\/li\u003e\n\u003cli\u003eMedian age was 67 (ranging from 44 to 83).\u003c\/li\u003e\n\u003cli\u003eDemographics: 80.9% male and 19.1% female.\u003c\/li\u003e\n\u003cli\u003eSmoking history: 72.3% were current or former smokers.\u003c\/li\u003e\n\u003cli\u003eHistology breakdown: 63.8% non-squamous cell carcinoma and 36.2% squamous cell carcinoma.\u003c\/li\u003e\n\u003cli\u003eGrade 3+ Adverse Effects included GI side effects at 14.9% and transient hypertension at 14.9%.\u003c\/li\u003e\n\u003cli\u003eNo treatment-related deaths were reported in this cohort.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyondSpring Inc. (BYSI) - VRIO Analysis: 6. SEED's RBM39 Degrader (ST-01156) Platform Access\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a pipeline option in the cutting-edge TPD space, evidenced by FDA IND clearance and Orphan Drug Designation for ST-01156.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eST-01156 received Rare Pediatric Disease and Orphan Drug designations from the FDA.\u003c\/li\u003e\n\u003cli\u003eThe Rare Pediatric Disease designation provides the potential to receive an FDA priority review voucher upon ST-01156 approval.\u003c\/li\u003e\n\u003cli\u003eThe Investigational New Drug (IND) application for ST-01156 received clearance from the U.S. FDA and China NMPA.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; access to a validated TPD platform with an IND-cleared asset is a rare opportunity for a clinical-stage firm.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSEED is advancing its lead candidate, ST-01156, a brain-penetrant RBM39 degrader, into clinical development.\u003c\/li\u003e\n\u003cli\u003eThe company plans to start first-in-human clinical trials of ST-01156 in Q1 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; the platform is built on SEED's proprietary technology and collaborations with firms like Eisai.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProprietary Asset\/Platform\u003c\/th\u003e\n\u003cth\u003eCollaboration Partner\u003c\/th\u003e\n\u003cth\u003eFinancial\/Structural Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProprietary RITE3™ platform\u003c\/td\u003e\n\u003ctd\u003eEisai Co., Ltd.\u003c\/td\u003e\n\u003ctd\u003eSEED is entitled to receive upfront and milestone payments of up to \u003cstrong\u003e$1.5 billion\u003c\/strong\u003e plus tiered royalties.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRBM39 Degrader (ST-01156) program\u003c\/td\u003e\n\u003ctd\u003eEisai Co., Ltd.\u003c\/td\u003e\n\u003ctd\u003eEisai led the Series A-3 financing first close of \u003cstrong\u003e$24 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTargeted Protein Degradation (TPD) technology\u003c\/td\u003e\n\u003ctd\u003eEli Lilly and Company\u003c\/td\u003e\n\u003ctd\u003eEli Lilly paid \u003cstrong\u003e$20 million\u003c\/strong\u003e in upfront cash and equity in 2020.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; SEED's successful $30 million Series A-3 financing shows external validation of the asset's potential.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSEED Therapeutics completed a \u003cstrong\u003e$30 million\u003c\/strong\u003e Series A-3 financing.\u003c\/li\u003e\n\u003cli\u003eThe Series A-3 financing was executed at a pre-money valuation of \u003cstrong\u003e$100 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe financing included a first close of \u003cstrong\u003e$24 million\u003c\/strong\u003e and a second close of \u003cstrong\u003e$6 million\u003c\/strong\u003e on September 22, 2025.\u003c\/li\u003e\n\u003cli\u003eFollowing transactions, BeyondSpring is expected to retain approximately \u003cstrong\u003e38%\u003c\/strong\u003e or \u003cstrong\u003e14.4%\u003c\/strong\u003e of SEED's outstanding equity interest.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the advantage is tied to the success of the SEED asset and BeyondSpring's equity position.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\u003cli\u003eBeyondSpring retains an equity position of approximately \u003cstrong\u003e14.4%\u003c\/strong\u003e in SEED Therapeutics.\u003c\/li\u003e\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyondSpring Inc. (BYSI) - VRIO Analysis: 7. Scientific Publications and Conference Data\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Third-party validation from high-impact journals (\u003cem\u003eThe Lancet Respiratory Medicine\u003c\/em\u003e) and key conferences (ASCO 2025, SITC 2025) builds credibility with investors and regulators. The Phase 3 DUBLIN-3 trial data was published in \u003cem\u003eThe Lancet Respiratory Medicine\u003c\/em\u003e, demonstrating a statistically significant survival benefit in second- and third-line NSCLC (EGFR wild-type) compared to standard-of-care docetaxel.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate; having data published in top-tier venues is a significant differentiator for a clinical-stage company.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Low; the specific data points, like the \u003cstrong\u003e85%\u003c\/strong\u003e DCR in a specific combination at SITC 2025, are unique.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: High; the company actively uses these publications to support its strategic business development. The company co-founded SEED Therapeutics, which successfully completed its \u003cstrong\u003e$30 million\u003c\/strong\u003e Series A-3 financing. BeyondSpring currently owns approximately \u003cstrong\u003e40%\u003c\/strong\u003e of SEED.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained; published scientific validation is a permanent part of the company's record.\u003c\/p\u003e\n\u003cp\u003eEfficacy Data from Key 2025 Conference Presentations:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eSITC 2025 Data (Plinabulin + Docetaxel + Keytruda, N=47)\u003c\/th\u003e\n\u003cth\u003eASCO 2025 Data (Plinabulin + Docetaxel + Pembrolizumab, N=47)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisease Control Rate (DCR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e85%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e77%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Progression-Free Survival (PFS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7.0 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6.8 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConfirmed Objective Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Duration of Response (DOR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7.2 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7.2 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e12-Month Overall Survival (OS) Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e79%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e78%\u003c\/strong\u003e at 15 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional Scientific and Financial Data Points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe SITC 2025 study involved metastatic NSCLC patients who progressed after prior PD-1\/L1 inhibitors.\u003c\/li\u003e\n\u003cli\u003eThe DUBLIN-3 Phase 3 trial compared Plinabulin plus docetaxel versus docetaxel alone in patients after disease progression on a platinum-based regimen.\u003c\/li\u003e\n\u003cli\u003eMechanism studies presented at SITC 2025 showed DC maturation and M1 macrophage polarization via a Plinabulin specific GEF-H1 dependent mechanism.\u003c\/li\u003e\n\u003cli\u003eSEED Therapeutics' lead RBM39 degrader program received U.S. FDA and China NMPA clearance for its Investigational New Drug (IND) application.\u003c\/li\u003e\n\u003cli\u003eSEED Therapeutics has a potential payment of up to \u003cstrong\u003e$1.5 Billion\u003c\/strong\u003e from a collaboration with Eisai.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyondSpring Inc. (BYSI) - VRIO Analysis: 8. Leaner Operational Cost Structure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Improved financial efficiency, with General and Administrative (G\u0026amp;A) expenses decreasing to \u003cstrong\u003e$0.8 million\u003c\/strong\u003e in Q3 2025 from \u003cstrong\u003e$1.7 million\u003c\/strong\u003e in Q3 2024, preserving cash, which stood at \u003cstrong\u003e$12.5 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025\u003c\/th\u003e\n\u003cth\u003eQ3 2024\u003c\/th\u003e\n\u003cth\u003eNine Months Ended 9\/30\/2025\u003c\/th\u003e\n\u003cth\u003eNine Months Ended 9\/30\/2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A Expenses ($ millions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.9\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses ($ millions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.6\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.9\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.2\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; many companies implement cost-cutting, but the reduction is notable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a result of specific internal headcount and consulting expense reductions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eLower professional service costs in consulting for business development and partnership initiatives.\u003c\/li\u003e\n\u003cli\u003eLower salary expenses driven by decrease in administrative headcount.\u003c\/li\u003e\n\u003cli\u003eLower company overhead expenses mainly due to decrease in investor relations services and D\u0026amp;O insurance related costs (Nine Months Ended 9\/30\/2025 vs 9\/30\/2024).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; management has clearly organized operations to reduce overhead while increasing Research and Development (R\u0026amp;D) spend to \u003cstrong\u003e$1.0 million\u003c\/strong\u003e in Q3 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; cost structures can change quickly with new strategic hires or renewed spending.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyondSpring Inc. (BYSI) - VRIO Analysis: 9. Current Liquidity Position\n\u003c\/h2\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eCash and cash equivalents stood at \u003cstrong\u003e$12.5 million\u003c\/strong\u003e as of September 30, 2025, following the SEED Therapeutics financing activities and strategic shift. Current assets were \u003cstrong\u003e$11.4 million\u003c\/strong\u003e as of the same date.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eLow; cash is a fungible asset, but the current level supports near-term operations following the SEED financing event. The cash position increased from \u003cstrong\u003e$2.9 million\u003c\/strong\u003e as of December 2024.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eLow; this is a balance sheet fact, not a replicable skill. The increase is attributable to the external financing of the co-founded entity, SEED Therapeutics, which closed a \u003cstrong\u003e$30 million\u003c\/strong\u003e Series A-3 financing.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh; the cash inflow related to the SEED divestiture and financing was deliberately positioned to fund Plinabulin research and regulatory activities. BeyondSpring holds an equity stake in SEED, which was \u003cstrong\u003e40.12%\u003c\/strong\u003e after the first closing in February 2025, with expectations for future sales to reduce ownership to approximately \u003cstrong\u003e~14%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eKey liquidity and balance sheet metrics as of the latest reported period:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAs of December 31, 2024\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Continuing Operations, Q3)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOperating expenses for the nine months ended September 30, 2025, included:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and development (R\u0026amp;D) expenses: \u003cstrong\u003e$2.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGeneral and administrative (G\u0026amp;A) expenses: \u003cstrong\u003e$3.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary; this number is subject to change based on the cash burn rate, which included R\u0026amp;D expenses of \u003cstrong\u003e$1.0 million\u003c\/strong\u003e for the quarter ended September 30, 2025, and future financing or SEED ownership sales.\u003c\/p\u003e\n\u003cp\u003eThe strategic use of funds is directed toward:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAdvancing Plinabulin research and regulatory activities.\u003c\/li\u003e\n\u003cli\u003eSupporting strategic business development and partnership initiatives.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516130680981,"sku":"bysi-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/bysi-vrio-analysis.png?v=1740152829","url":"https:\/\/dcf-model.com\/products\/bysi-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}